Home > Haematology > Adding ivosidenib to azacitidine improves survival in IDH1-mutated AML

Adding ivosidenib to azacitidine improves survival in IDH1-mutated AML


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The New England Journal of Medicine
Reuters Health - 20/04/2022 - Survival was more than twice as long when the Servier drug ivosidenib was added to azacitidine in 146 patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML), according to results of the phase-3 AGILE trial. After a median follow-up of 12.4 months, event-free survival was 36% in the ivosidenib-azacitidine group versus 16% in the placebo-azacitidine group (hazard ratio, 0.33; P=0.002). A complete remission was seen in 47% of ivosidenib patients and 15% with placebo, according to Dr. Pau Montesinos of Hospital Universitari i Politecnic La Fe, in Valencia, Spain, and colleagues. Median overall survival was 24.0 months with the two-drug combination compared with 7.9 months in the placebo group (P=0.001), the researchers report in the New England Journal of Medicine. Rates of neutropenia and bleeding were higher with ivosidenib, but the incidences of infection and febrile neutropenia were lower. The compa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on